FDA D.I.S.C.O. Burst Edition: FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma
0:00
3:30
Listen to a soundcast of the April 19, 2023, FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma.
Fler avsnitt från "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Missa inte ett avsnitt av “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” och prenumerera på det i GetPodcast-appen.